BF Biosciences Limited (PSX:BFBIO)
130.90
-1.72 (-1.30%)
At close: Nov 6, 2026
BF Biosciences Ratios and Metrics
Market cap in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 11,563 | 12,621 | 14,902 | - | - | - | |
Market Cap Growth | -15.21% | -15.30% | - | - | - | - |
Enterprise Value | 12,632 | 13,450 | 15,314 | - | - | - |
Last Close Price | 130.90 | 142.88 | 168.70 | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
PE Ratio | 17.60 | 19.97 | 33.33 | - | - | - |
Forward PE | - | 22.57 | 22.57 | - | - | - |
PS Ratio | 1.18 | 1.33 | 2.55 | - | - | - |
PB Ratio | 2.11 | 2.38 | 3.20 | - | - | - |
P/TBV Ratio | 2.11 | 2.39 | 3.20 | - | - | - |
P/OCF Ratio | 67.31 | - | 49.71 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
EV/Sales Ratio | 1.29 | 1.42 | 2.62 | - | - | - |
EV/EBITDA Ratio | 9.03 | 9.89 | 16.58 | - | - | - |
EV/EBIT Ratio | 11.31 | 12.38 | 20.93 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Debt / Equity Ratio | 0.30 | 0.31 | 0.37 | 0.94 | 1.32 | 0.96 |
Debt / EBITDA Ratio | 1.19 | 1.19 | 1.87 | 2.97 | 8.59 | 6.45 |
Debt / FCF Ratio | - | - | - | 4.24 | - | - |
Net Debt / Equity Ratio | 0.20 | 0.20 | 0.05 | 0.80 | 1.11 | 0.02 |
Net Debt / EBITDA Ratio | 0.77 | 0.77 | 0.23 | 2.54 | 7.26 | 0.13 |
Net Debt / FCF Ratio | -1.57 | -1.65 | -8.68 | 3.63 | -1.02 | -0.04 |
Asset Turnover | 1.07 | 1.09 | 0.83 | 0.64 | 0.36 | 0.41 |
Inventory Turnover | 2.29 | 2.25 | 2.70 | 2.44 | 2.16 | 2.79 |
Quick Ratio | 0.43 | 0.42 | 1.07 | 0.40 | 0.39 | 2.47 |
Current Ratio | 1.81 | 1.93 | 2.36 | 1.17 | 1.13 | 3.21 |
Return on Equity (ROE) | 12.77% | 12.70% | 12.74% | 17.79% | 7.85% | 18.65% |
Return on Assets (ROA) | 7.58% | 7.83% | 6.52% | 7.70% | 3.33% | 4.08% |
Return on Invested Capital (ROIC) | 10.42% | 11.48% | 9.90% | 11.15% | 6.58% | 14.48% |
Return on Capital Employed (ROCE) | 15.80% | 15.80% | 11.20% | 16.00% | 6.30% | 6.50% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Earnings Yield | 5.68% | 5.01% | 3.00% | - | - | - |
FCF Yield | -5.90% | -4.99% | -0.17% | - | - | - |
Buyback Yield / Dilution | -1.41% | -9.14% | -27.79% | - | -0.01% | - |